Skip to content
approvedImmune & Inflammation

Thymalin

Also known as: Thymic peptide extract, Thymaline, Thymarin

Thymalin is a polypeptide extract from calf thymus glands developed in Russia by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. Approved in Russia for immunodeficiency conditions, it is the foundational product of Khavinson's peptide bioregulation theory, which proposes that short peptides can regulate gene expression in specific tissues. Clinical studies in Russia report immune restoration in immunocompromised patients, reduced infection rates, and potential anti-aging effects through telomerase activation.

4 cited references·5 researched benefits

Quick Answer

Thymalin is a thymic polypeptide extract developed by Vladimir Khavinson at Russia's Institute of Bioregulation and Gerontology. Approved in Russia for immunodeficiency, it restores T-lymphocyte function and thymic hormone production. Khavinson's long-term studies report reduced mortality rates in elderly patients over 6–15 year follow-ups. It is the prototype for the Khavinson peptide bioregulator approach, which has produced dozens of tissue-specific short peptide preparations. Not approved outside Russia.

Key Facts

Mechanism
Thymalin contains a mixture of thymic polypeptides that interact with DNA to regulate gene expression in immune cells. The primary mechanism involves restoration of T-lymphocyte differentiation and maturation, particularly CD4+ helper and CD8+ cytotoxic T cells. It upregulates thymic hormone production (thymulin, thymopoietin, thymosin) even in the aged, atrophied thymus. Additional reported mechanisms include telomerase activation in human lymphocytes, correction of melatonin and cortisol circadian rhythms, and modulation of cytokine profiles (shifting toward Th1 immune responses). These effects are proposed to occur through direct peptide-DNA interactions that regulate chromatin accessibility.
Research Status
approved
Half-Life
~2–4 hours (estimated)
Primary Use
Immune & Inflammation
Table of Contents

Benefits

  • Immune restoration — restores T-lymphocyte counts and function in immunocompromised patients, including post-surgical and post-radiation statesmoderate
  • Infection rate reduction — clinical studies in elderly populations report 30–40% reduction in acute respiratory infectionsmoderate
  • Mortality reduction — Khavinson's longitudinal studies (6–15 years) report reduced mortality in elderly cohorts receiving thymalin + epithalonpreliminary
  • Thymic rejuvenation — may partially restore thymic function in age-related thymic involutionpreliminary
  • Bioregulation foundation — validated the concept that short peptides can regulate tissue-specific gene expressionpreliminary

Dosage Protocols

RouteDosage RangeFrequencyNotes
Intramuscular injection5–10 mgDaily for 5–10 daysStandard Russian protocol: 5–10 mg IM daily for 5–10 days, repeated every 3–6 months as needed. Approved in Russia for secondary immunodeficiency, post-surgical immune suppression, and age-related immune decline.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Injection-site reactions — pain, redness at intramuscular injection sitecommon
  • Allergic reactions — possible sensitivity to animal-derived thymic peptide extractrare
  • Fever — transient low-grade fever reported in some patients during initial treatmentrare

Frequently Asked Questions

What is the Khavinson peptide bioregulation theory?
Vladimir Khavinson, a Russian gerontologist, proposed that short peptides (2–4 amino acids) serve as natural bioregulators that interact directly with DNA to modulate gene expression in specific tissues. His work began with thymalin (thymus extract) in the 1970s, leading to the development of over 20 tissue-specific peptide bioregulators (epithalon for pineal, cortagen for brain, cardiogen for heart, etc.). The theory suggests that aging involves progressive loss of peptide bioregulation, and exogenous peptide supplementation can partially reverse this decline. The approach is widely accepted in Russia but has limited validation in Western peer-reviewed literature.
Is thymalin available outside Russia?
Thymalin is not approved by the FDA, EMA, or other Western regulatory agencies. It is available in Russia as an approved immunomodulatory medication. Some peptide suppliers sell thymalin for research purposes internationally, but these products lack the quality controls and regulatory oversight of pharmaceutical-grade preparations. Thymosin alpha-1 (Zadaxin) is a related thymic peptide with more international clinical data and regulatory approvals in several Asian countries.
How does thymalin differ from thymosin alpha-1?
Thymalin is a crude polypeptide extract from calf thymus containing a mixture of peptides, while thymosin alpha-1 (Tα1) is a single, defined 28-amino-acid peptide. Tα1 was isolated and characterized by Allan Goldstein at George Washington University and has undergone rigorous Western clinical trials for hepatitis and immune enhancement. Thymalin has primarily Russian clinical data with less standardized composition. Both target immune function, but Tα1 has a more defined mechanism and broader international acceptance.
What evidence supports thymalin's anti-aging effects?
Khavinson published longitudinal studies in which elderly patients (60–80+ years) received thymalin + epithalon courses over 6–15 years. He reported 28–46% lower mortality rates versus control groups. These studies were published in Russian journals and some international publications. Criticism includes: relatively small sample sizes, non-randomized designs, potential confounders, and limited replication by independent groups. The mechanism proposed — telomerase activation and circadian rhythm normalization — is biologically plausible but requires larger, rigorous trials for definitive evidence.

References

  1. 1
    Peptide bioregulation of aging: results of 35-year research(2011)PubMed ↗
  2. 2
    Thymic peptides in the treatment of immunodeficiency: clinical experience with Thymalin(2005)
  3. 3
    Effect of Thymalin and Epithalon on mortality in elderly patients: 15-year follow-up(2003)PubMed ↗
  4. 4
    Short peptides and their role in gene expression regulation: the bioregulation approach(2014)PubMed ↗

Latest Research

Last updated: 2026-02-19